INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 171 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is 0.70 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $1,008,000 | -20.3% | 10,000 | 0.0% | 0.12% | -28.2% |
| Q3 2018 | $1,264,000 | +50.7% | 10,000 | 0.0% | 0.17% | +24.1% |
| Q2 2018 | $839,000 | +290.2% | 10,000 | +185.7% | 0.14% | +204.4% |
| Q1 2018 | $215,000 | +5.4% | 3,500 | 0.0% | 0.04% | -61.9% |
| Q4 2017 | $204,000 | -77.3% | 3,500 | -50.0% | 0.12% | -77.9% |
| Q1 2016 | $899,000 | -14.0% | 7,000 | 0.0% | 0.53% | -2.2% |
| Q4 2015 | $1,045,000 | -10.0% | 7,000 | 0.0% | 0.55% | -3.2% |
| Q3 2015 | $1,161,000 | -31.3% | 7,000 | 0.0% | 0.56% | -35.8% |
| Q2 2015 | $1,690,000 | -14.4% | 7,000 | 0.0% | 0.88% | -16.1% |
| Q1 2015 | $1,974,000 | -9.6% | 7,000 | -50.0% | 1.05% | +65.6% |
| Q4 2014 | $2,184,000 | – | 14,000 | – | 0.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Carmignac Gestion | 2,028,192 | $229,389,000 | 1.76% |
| Orbimed Advisors | 1,037,000 | $117,285,000 | 1.33% |
| BB BIOTECH AG | 255,719 | $28,922,000 | 0.95% |
| ALTRINSIC GLOBAL ADVISORS LLC | 193,369 | $21,870,000 | 0.74% |
| FALCON POINT CAPITAL, LLC | 44,573 | $5,041,000 | 0.67% |
| Rhenman & Partners Asset Management AB | 30,000 | $3,393,000 | 0.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 11,155 | $1,262,000 | 0.48% |
| NATIONAL PLANNING CORP | 52,400 | $5,888,000 | 0.44% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 364,232 | $41,195,000 | 0.38% |
| SPHERA FUNDS MANAGEMENT LTD. | 15,000 | $1,697,000 | 0.33% |